Please attach a **blank** copy of form(s) used by the IACUC/OB to review and approve studies. Include forms used for annual (or other periodic) renewal, modifications, amendments, etc., as applicable.

The following protocols are included in Appendix 9:

- 1. Annual renewal form
- 2. Personnel update form
- 3. Protocol form: Three different versions of the IACUC protocol form exist due to an ongoing transition from a paper-based application to an electronic application.
 - a. Protocol form (a) (in use until 2016-to be phased out by end of 2019)
 - b. Protocol form (b) (to be phased out within 3 years)
 - c. Electronic protocol form (c) (implemented in July, 2019; most protocols expected to be transitioned within 3 years).
- 4. Importation protocol
- 5. Holding protocol
- 6. Off-site protocol
- 7. Unanticipated Adverse Event(s) Form

1. Annual Renewal of Animal Use Protocols

ANNUAL RENEWAL OF ANIMAL USE PROTOCOL

Complete this form at the end the form as soon as the IACL Submit completed-signed form 856-5384 with questions regarders.	JC Office send in to Casey Mo	ds you a remin oran in the Off	ider.	·		
1) Docket #:		Pl:				
2) Phone:		Department				
3) Primary Contact Person:						
Phone:		Campus/Bu	ilding			
4) Title of Protocol:	•					
5) Date of your last full-protoc	ol approval (n	ew or 3 year r	enewal):			
6a) Please indicate the total number of animals used (including those NOT used in experiments, but euthanized) in the last year of approval. Contact Eva Miele (508-856-4409) if the Department of Animal Medicine, if you have questions about animals ordered or transferred during the past year.						
Species		nimals used in			Total	
	B (breeding)	С	D	E	number	
6b) If you have transferred at protocol, please indicate the f Protocol number:			ng protocol in s/no of animal:		to this	
7a) Have there been any adverse reactions, spontaneous deaths, or any other problems with the animal model over the past year Yes No If "yes", please explain:						
7b) Has the frequency of ser predicted?	·	cted, adverse	reactions bee	n greater than	ı	
Yes If "yes", please expla	No in:					
8) Does this protocol have pro	evious Instituti	onal Biosafety	Committee (I	BC) approval?	,	

Rev. 1/09

Please indicate with an "X"

		Approved: Not Approved	IBC Docket Number Not Required				
	Please	call the IBC Office (508-856-1572), it	you have any questions.				
8)	Are you Yes	u using areas/satellite labs <u>outside</u> o No	ne of the main animal facilities?				
		If " yes ", please list: (a) Campus/Building (location): (b) Floor/Room #'s:					
9)	Have	there been any changes in personne List omissions of personnel not previ	I during the year? ously reported to IACUC via amendment(s)				
		animals. It is a violation of UMMS IA	have been done prior to start working with CUC policy, if someone started working with you are adding new personnel at this time,				
	ogress		elow to write a very brief summary of the ot be a technical report – use language				
	compl		ny knowledge, the information provided is h study is proceeding in accordance with				
	Princip	al Investigator	Date				
		För (ACU	: Use Only)				
	Reviewed and Approved by the IACUC						
	Chair/\	Vice-Chair, IACUC	Date				
	1 /00						

2. Personnel update form



UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE PERSONNEL REQUEST FORM

To add personnel to an approved IACUC protocol, please complete this form and email to: IACUC@umassmed.edu. Please note that the personnel must complete the following before they can be added to an approved protocol:

- Receive Health Clearance from Employee Health and Safety (Complete this <u>form</u> and email to EmployeeAnimalHealth@umassmemorial.org)
- Complete online training through AALAS Learning Library (Module 1, Module 2 and the species-specific training for all species listed on the protocol; Link for <u>AALAS</u>)

If you have any questions, please email the IACUC office inbox (IACUC@umassmed.edu)					
Docket #:					
Project title:					
Name of the PI:					
Department:					
Name (new personnel):					
 Email: UMMS user ID (i.e. SmithA): Summary of experience (Format: Experience with [enter species] since [enter date] (repeat as needed). This includes performing [enter complex procedure, such as surgery] since [date] (repeat as needed)): 					
Species to be used:					
List procedures to be conducted (e.g. Euthanasia, breeding, survival surgery):					
Personnel responsible for training:					
Additional hands-on training received which may be required, please see notes below:					
Introduction to Aseptic Techniques (if conducting survival surgery), date completed:					
Herpes B Virus Training (if working with Macaques), date completed:					
Q Fever Training (if working with Sheep), date completed:					
Animal Medicine Rodent Euthanasia Training (personnel with less than one year of experience), date completed:					
Personnel Removal:					
PRINCIPAL INVESTIGATOR'S SIGNATURE : DATE:					

3a. Protocol



UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE Animal Study Protocol

h-	т !	1		T 1 . 11 A	
P	I • '	1		Llocket# A_	
II.	1. ·	,		DOCKEL# A-	
<u> </u>			 		

Instructions for IACUC Animal Study Protocol application:

- 1. Complete the Animal Study Protocol application form if you are applying for a new, 3-year renewal or *major amendment.
- 2. If you need assistance in developing an Animal Study Protocol or have any questions, please contact IACUC@umassmed.edu
- 3. Save your file as [Your last name-IACUC] and e-mail the completed document as an attachment to IACUC: IACUC@umassmed.edu
- 4. Print a copy and collect signatures where appropriate: send the hard copy to IACUC, Office of Research, S1-859

All Principal Investigators are required to fill out the application face page (next page) and the sections I through X of the Animal Study Protocol. In addition, please complete appropriate forms and check the boxes below.

Forms: Double cli	ck on checkboxes to mark
(\mathbf{A}_{ijk})	Transporting animals for use outside of or to another area of the animal facilities
B	If animals are going to bred for the use in this protocol
Garren and a	Using anesthesia
D	Doing survival surgery
Ends King To The State	Administering substances other than anesthetics (therapeutic agents) toxins) cells, cell lines?
	cell/tissue extracts; viruses and other infectious agents, purified biological products, etc.) 🕍 🦭
	Will rodent cell lines, serum, or tissues be introduced into live animals?
F	Food or water restriction, prolonged physical restraint or animal care done by lab staff
G	If using radioactive agents, hazardous chemicals, recombinant DNA, breeding transgenic
	animals carrying viral genes or synthetic nucleic acids (see form G for details), infectious
	agents, biotoxins, human or non-human primate materials and live non-human primates
H	To indicate adverse effects of procedures and experiments/monitoring and managements ::: **
Ī	If using any of the UMMS Core Facilities
J	If using sites or vendors outside UMMS
K	If you are conducting a training course
Worksheet 1	Animal number worksheet
Worksheet 2	Breeding worksheet
	

Please send a cover letter indicating what part of the protocol you are changing, and justify the reason for requesting the change. In the protocol-form use a *different font* or different color for the section that you wish to amend or to change.

^{*}Major amendment: Any change that could affect the well being of animals (addition of surgical procedures, use of hazardous agents as infectious agents or radioisotopes), change of animal species.

. P. day			
	APPLICATION	TO USE VER	Docket No. A- RTEBRATE ANIMALS
	IN RES	EARCH OR II	NSTRUCTION e and Use Committee
Principal	Name and Highest Acade Degree(s)		<u> 1909 - Sandra Arton, i strummerte e en entre di de la la la la la entre di Sueriga è desig</u>
Investigator	Faculty Title		
	Department \ Division or		· · · ·
	Company Name	·	
	Mailing Address or UMMS Building	3.	
	E-mail Address		
	Contact Phone Numbers	Office: Pager #:	Home:
Faculty Sponsor	Name and Degree		
(if required) or co-	Faculty Title		
investigator	Department/Division]	
		I	
	Name	- 	
Primary Contact	Telephone No.	Office	Home
Person	Mailing Address		
	Building		
Project Title	П		
New 3-Y	Year Renewal M	lajor Amendment (sta	ate changes in a cover letter)
is to assist investigat	ou like to receive an informa ors in improving the protoce ee review). You may not rec	al technical review and col and minimizing co quire this option, if you	feedback from the IACUC office. The intent of this service oncerns during the formal review (veterinary pre-review are experienced in writing IACUC protocols.
	USE	OF THIS APPLICA	ATION FORM
	formatting of this document inimum and not replace ans		ACUC MUST include shading. If attachments are used,
		•	contact the IACUC office (508.856.5384).
Please note that public	upon request the University	may be required by la	w to release a copy of this application to the
			Name (Please Print or Type)
			()
Signature of Depart		Date	
For IACUC USE ONL	Y:		
Approved:	Yes No)	
Approved with condition			
, .pp. 0.00 min oonalii			
Date	Chair/Vice	e Chair, IACUC	

Section I. OBJEC	TIVES OF PRO	POSED RESE	ARCH OR INSTR	UCTION	
a. Check the box belo	ow that describes the	type of animal use	oeing proposed.	3	2 10 10 10 10 10 10 10 10 10 10 10 10 10
☐ Basic Research		Service (Cores, Sent	inels, etc.)	Instruction or Train	ing
☐ Field Research	7	esting (Biologicals,	Toxicity, etc.)	Applied Research	
Other					
b. Lay Summary: In cle summarize the backgro	ar, concise, <u>non-tech</u> ound and objectives o	<i>nical,</i> language (i.e. f your studies involv	, that could be understooning animals.	od by someone at a h	igh school level),
	nis should serve as		describing the specific y of the proposed stud		
d. Briefly <u>explain the re</u> scientific knowledge.	levance of the propos	sed research or instr	uction to human or anim	nal health and/or to th	e advancement of
e. Has this project unde	ergone scientific peer	-review?			
Yes No					
a. Briefly explain why a	nimals are required f	or your studies.	ALTERNATIVES T	OTHE USE OF	ANIMALS
b. Briefly explain why th	ne species you propo	se to use is/are the	most appropriate.	. ·	
			als and to minimize the le ; doing pilot studies, usin		
	SEDIAE WEIGHT	*O/BEONEONE			to the supplied while of the court of the
			D: PAIN / DISTRE		A Carrie to Control
By NIH policy, you IACUC to initially review	n will still have to rea or all animal activities or accounted for, inclu	n <mark>ew your protocol</mark> described in your gr	every 3 years. This requant proposal, irrespective (rats and mice) and ne	uirement is independe e of the grant's time p	period.
			listed in categories C, D htype and/or sex, (Categ		plus all animals
Species	Number in Pain / Distress Level B (to be used only for USDA - covered species)	Number in Pain / Distress Level C	Number in Pain / Distress Level D	Number in Pain / Distress Level E	Total (should agree with numbers in worksheets I and II, if used.)
		· · · · · · · · · · · · · · · · · · ·			

Pain / Distress level indicates maximum pain or distress level to be experienced by animal(s):

B = being bred but not used in testing, teaching or experiments (USDA covered species only)

C = negligible;

D = pain / distress relieved by appropriate drug use;

- E = pain / distress not relieved by appropriate drug use. See the IACUC Instructions for definitions and examples.
 - No Category B is to be used for rodents. Rodents that were once considered to be Category B should be listed under Category C.
 - Induction of tumors is Category C if no distress is anticipated or if you monitor the status of animals and euthanize sick animals when detected.
 - > Mice used for Ascites Production are always Category "E".
- b. If you have animals in category E, use this space to provide a description of the procedures producing pain or distress, and list the reasons why pain-relieving drugs cannot or will not be used to relieve pain or distress. If pain/distress relief would interfere with test results, justify why that is true.
- c. Are you planning to reuse animals that were previously used for any other experiments or procedures under a different animal protocol?

Yes No If the answer is "yes," please provide more details (number of animals, protocol number, what previous procedures done in these animals)

d. If there are federal guidelines or regulations that <u>require</u> the use of laboratory animals then use this space to cite the agency, CFR title, number and specific section (e.g., Food and Drug Administration, 21:CFR1030.110).

Section IV. JUSTIFICATION OF THE NUMBER OF ANIMALS REQUESTED

NIH rules require that animal use must be kept to the minimum consistent with a sound scientific outcome. Please use the space below to justify that the number of animals requested is appropriate for the goals of the experiments.

- a. Write a brief description of experimental design. In a table below (for large number of animals, please attach an animal number worksheet in the appendix), show all of the experimental groups and the number of animals per group. Be sure that the totals in the table match the totals shown in section III (Number of Animals Requested). Provide a science-based justification for why you chose the number of animals needed per group or other division of your research.
- b. Describe, in general terms, the statistical tests required for the study.

a. Describe the age/weight, sex,	CIFICS and source of each animal species/stra	in.	<u> </u>
SPECIES / STRAIN	AGE / WEIGHT	SEX	*VENDOR
			·
*Note that the UMass Transgenic	Core should be listed as a vendor if ar	simals are produced there for	or you If you are receiving
animals from another investigato	r, indicate the name of the PI and proto	col number.	
b. If any of your animals have sp be socially housed, please expla	ecial needs, use the space below to list	needs for special handling	or housing. If animals cannot

c. Specify what parameters you will assess to ensure that the animals are healthy before your experiments begin. Check

all boxes that apply.	·				
Activity	Appearance	Appetite		Behavio	эг
Excreta	Respiratory Pattern	Temperature)	Weight	t
Laboratory tests or other observations (specify)					
Section VI. EXPERIMENT may lead to a permanent p IACUC reviewed procedures			surgery and	procedu	res that
a. Basic chronology (please use a t	flow chart or a sequential list of a	ctivities)			
b. Detailed description of procedure carried out on living animals from in		ro procedures): Descril	oe in narrative fo	rm all proce	edures to be
c. Indicate how you will identify anim	mals				
d. Will the studies result in adverse	effects on animal health or well	being?			
Yes No If yes, please com	· · ·	· · · · · · · · · · · · · · · · · · ·			
Section VII. TERMINATIO	N OF STUDY / EUTHAN	ASIA			
Unless specified otherwise by the F behalf of the Principal Investigator euthanasia guidelines of the Americusing methods approved by the UN	will do so using any method listed can Veterinary Medical Associati	d as acceptable for the on. Neonatal and pregi	species in the m	ost recent	edition of the
a. Is death used as an endpoint in die as a result of experimental ma earlier end point is not acceptable.	this study? Death as an endpoin nipulation, i.e. <u>exclusive</u> of planr	t means that the anima led euthanasia. If yes,		Yes	No
b. What criteria will be used to perf	orm euthanasia earlier than plan	ned?			
	·				
c. Other Use – Will animals be ava http://i.umassmed.edu/ExchangeBo		estigators? Link to the	Animal Medicine	Exchange	Board at
 d. Describe the method(s) of eutha Government policy requires the use Must comply with the American Ve 	e of pharmaceutical grade drugs			ose and rou	ite below. US
Species	Method/Drug		Dose (mg/kg bo	ody wt.)	Route
	<u>. </u>				
e. Current rules require that after e done after euthanasia using CO ₂ . I	uthanasia, death be confirmed by ndicate below how you will doub	y using a second meth e kill your animals.	od. For example	bilateral pn	eumothorax

Section VIII, DATABASE SEARCHES

In the space below, document that you have searched databases

- To determine that you are not unnecessarily duplicating previous experiments,
- To determine that alternatives to animal use are either not available or not appropriate, To determine that procedures involving animals will avoid or minimize discomfort, distress and pain, AND

¹A pharmaceutical grade compound is a drug, biologic, or reagent that is approved by the Food and Drug Administration (FDA) or for which a chemical purity standard has been established by the <u>United States Pharmacopeia-National Formulary (USP-NF)</u>, or <u>British Pharmacopeia (BP)</u>.

 To determine that alternatives to procedures that may cause mo have been considered 	ore than momentary or slight pain or distress to the animals
Sources of information regarding possible duplication and alternatives inc • Medline (http://www.ncbi.nlm.nih.gov/pubmed) • Animal Welfare Information Center (awic.nal.usda.gov/) • UMMS veterinarians (508.856.3151)	clude:
 National Agricultural Library (www.nal.usda.gov/) WWW Virtual Library of Veterinary Medicine (http://netvet.wustl.edu/vetme Altweb (http://www.jhsph.edu/~altweb) a. Dates of Searches: 	ed.htm)
b. Name of the database(s) you searched:	
c. Years Covered by Searches:	· · · · · · · · · · · · · · · · · · ·
d. Keywords Searched:	
e. Other Sources of Information:	

	monang manan	minute at the	time of this application.					
Name	UMMS Phone	Emer- gency Phone	What are this person's responsibilities with animals on this study?	Years of experience with the technique to be used	Years of experience with the technique in species to be used	² First time animal user at UMMS (Yes/NO)	³ On-line training courses completed (Yes/No)	4Occupational health
				-				
				1				
				1				
				1				
				<u> </u>	 			
				_				
				-				

ADDITIONAL NOTES ON PARTICIPATING PERSONNEL:

- Before other new personnel perform any procedures, a written minor amendment request must be submitted to and approved by the IACUC. All personnel new to UMMS or those who never worked with animals will have to complete all the Training and Occupational Health and Safety Requirements before added on an IACUC protocol.
- The principal investigator is responsible for ensuring that all personnel adhere to the conditions approved by the IACUC.

Section X. APPLICANT'S CERTIFICATION

IACUC is charged with carrying out the rules and regulations of the Federal Government's Animal Welfare Act governing the care and use of animals in research and instruction. The Act stipulates that (a) Principal Investigators must give written assurance that the activities do not unnecessarily duplicate previous experiments; (b) procedures involving animals must avoid or minimize discomfort, distress, and pain to the animals; (c) Principal Investigators must consider alternatives to procedures that cause more than momentary or slight pain or distress to the animals and give a written description of methods used to determine that alternatives are not available; and (d) paralytic agents cannot be used in unanesthetized animals. Accordingly, the Applicant, who must be a member of the faculty holding Principal Investigator status, is required to read and sign the following certification:

BY SIGNING BELOW, I CERTIFY THE FOLLOWING:

- 1. I am thoroughly familiar with the literature in the field of research proposed in this application, and I have determined that the research does not unnecessarily duplicate experiments, that appropriate non-animal models are not available, and that the research must be conducted on living animals.
- 2. I will abide by all UMMS policies and procedures regulating use of animals in instruction and research, by the provisions of the PHS/NIH Guide for the Care and Use of Laboratory Animals, and by all other applicable laws, policies, and regulations governing the use of animals in instruction and research.
- 3. I will supervise all experiments involving live animals. Furthermore, I will ensure that all listed participants are qualified or will be trained in proper procedures, including animal handling, anesthesia, surgery, post-procedural management, and euthanasia. Also, I will ensure that individuals not listed in the application will not have responsibility in experiments involving animals.
- All listed personnel will read the IACUC-approved Application to Use Vertebrate Animals in Research or Instruction before
 undertaking any procedures on laboratory animals.
- 5. Survival surgery will be performed using standard aseptic procedures.

Pl's Signature:

- Animal Medicine clinical veterinary staff will be consulted as needed to ensure satisfactory veterinary care.
- 7. In the event of an animal health emergency, my staff or I will contact the Department of Animal Medicine. We will not attempt animal treatment by ourselves, unless it is a life-threatening emergency.
- 8. If I cannot be contacted, and animals in this project show evidence of illness or pain, emergency care, including euthanasia, may be administered at the discretion of the Animal Medicine veterinary staff.
- Significant changes in study objectives and procedures require IACUC approval.
- 10. Unanticipated adverse events will be reported to the IACUC as required by UMMS IACUC policy
- 11. This application meets all animal use and care requirements of the funding agencies that have been asked to support the research.
- 12. By signing below, I certify that all animal studies described in grant proposals using this protocol are described in this animal use application.

Date:

GRANTS ASSOCIATED WITH THIS A	NIMAL PROTOCOL	
Sponsor	Funding period	Grant ID #

\$ 1. 多类的 1. 多种 1. 多种 1. 多种 1. 多数 1.		
A1. Will animals be used in areas, e.g., laboratories, outside one of the general animal facilities?	Yes	No
(A Level, BioTech II, BNRI 1st floor, LRB 1st floor, Rose Gordon, ASC Facility)		
If "yes", list the building and room number(s) where animals will be housed or used outside the animal facility.		
A2. Indicate which of the following procedures will be used outside of the animal facility:		
Fluid Collection/Tissue Harvesting Non-Surgical Procedure Non-Survival Surgery Surv	ival Surgery	
Irradiation Core Service/Imaging Other:		
A3. Will animals be held, housed, and/or used in study areas outside of the animal facility for more than 12 hours for USDA regulated species or 24 hours for non-USDA regulated species?	Yes	No
If "Yes", in the space below list the building and room number(s), and justify scientifically the need to hold animals.		
noid animais.	L	
Ad the this page to depart he have considered as the control facility to a deal of the control facility to a		
A4. Use this space to describe how you will transport animals from the animal facility to a study area ou	tside of the ani	mai facility
A5. Is a patient procedural area to be used for animal studies?	Yes	No
If "Yes", use the space below to provide room number and/or location of patient area.		
If animals are to be transported to the patient area, you will require the approval of the Infectious Disease Committee (ICC). Please fill out the ICC Approval form and send to Mack, Deborah Ann		
(Infection Control) (UMMHC) DeborahAnn.Mack@umassmemorial.org. Contact Deborah Ann Mack		
at 508-856-5843, if you have questions.		
A6. If "Yes", describe any special animal transport or facility procedures that will be followed to assure ranimals and patients.	ealth and safe	ty of both
A7. Will animals for your use be transported to a different area of the animal facility or to a different UMI If yes see below.		lity? Yes.
I agree to use the Web Animal Ordering System for all transfers within the animal facility, except as	noted below.	
Our work requires that we transport of animals to different areas of the animal facility for activities ap irradiator, biocontainment suite. Explain very briefly below.	proved by the I	ACUC e.g.

		EREEDING			
Use this section if you are breeding B1. Describe the species, strain, a	ig animals for this proj	ect.			
SPECIES / STRAIN	AGE		weight	VENDOR	· · · · · · · · · · · · · · · · · · ·
000 ; 0			***E (O(1)	VENDOR	
00.0	30				
B2. Specify what parameters you Activity	will assess to ensure t		ealthy. Check all bo		
•		Appearance		Appetite	
Excreta		Respiratory Pattern		Temperature	
Laboratory tests or				1	<u>. </u>
other observations					
(specify)					
B3. In this space describe how ma	I any animals you antici	pate breeding over th	e next 3 years. Brief	ly explain your calcu	lations
201011.					
B4. Anticipated health problems in animals you are proposing to bree	n the animals being br	ed. If there are known	n health or well being in dotail	issues associated v	vith the
ariinais you are proposing to bree	d, or their onspring, p	lease describe trieff	ii detaii.		
B5. Male Female Ratio	A ratio of 1:1 wi	ill be used. No continu	Jous breeding		
	lп		Ū		
	A ratio of 1:1 wi	ith continuous breedir	ng will be used. See	below	
	A ratio of 1:2 or 1:3 will be used (harem breeding). See below				
	I have read the IACUC Mouse Breeding Policy that prohibits more than one litter per cage. I agree to separate pregnant females to other cages prior to their giving birth in				
		eparate pregnant fem เกd to wean continuoเ			
	nate in breeding a	and to wear continuot	isiy bred fillers al da	y Z i ii tile leiliale is į	regnant.
Mouse Breeding Policy B6. If your animals have special needs, use the space below to list needs for special handling or housing.					
B6. If your animals have special n	eeds, use the space b	pelow to list needs for	special handling or	housing.	
		· · · · · · · · · · · · · · · · · · ·			
B7: Describe how you will identify	your animals (e.g. ea	r tags):			
			*		
B8. Use this space to describe what will be the disposition of retired breeders or any excess animals.					
bo. Ose this space to describe what will be the disposition of rethed preeders of any excess affilials.					
B9. Will you require special caging? (If so it is your responsibility to provide it)					
B10. How often will each male and female be bred?					
P11 If you will be using introd or outbred enimals describe however will applied that the control is a supplied to					
B11. If you will be using inbred or outbred animals, describe how you will ensure that they remain in- or outbred:					
B12. Describe any special handling that you anticipate:					
B13. Will males be removed from cages before birthing?					

Yes No	
(if no, explain why not)	
B14. What nesting materia	als will you use?
(For rodents, conside	er Nestlets or similar material)

B15. At what age will the young be weaned?	
B16. Will the offspring be genotyped, and if so, at what age and by what method?	
B17. Will mice be bred and transferred to other investigators? YES NO	
If yes please check the attestation I agree that all transfers to another investigator whether within the Animal facility or directly to a laboratory must use electronic Web Animal Ordering system. I understand that failure to do so represents unapproved animal use under the donating investigator's (my) protocol and I will be responsible for all regulatory issues, violations, etc arising from such use Use of animals not on the recipient's protocol also represents a protocol violation of his/her protocol.	

	A Children	LEFORMO!			
		ANESTIHESIA Anestiesiarang/Analoesia			
C1. PRE-ANESTHETIC AGENTS	(e.g., tranquilizers,		to be the second of the second	w these agents will be used	
in your studies. If none will be use				, and the second	
Frequency of administration	Species	Pre-anesthetic Agents & Anesthetic Agents	Dose	Route/Volume	
]					
C2. MONITORING OF ANESTHE noxious stimulus) and (b) how free			eal reflex, heart rate, i	respiration, response to	
A form (suggested template) for recording Rodent Anesthesia and Analgesia can be obtained from the IACUC website: RODENT ANESTHESIA RECORD FORM					
		•			
C3. Use of Isofluorane: It is IACU(policy on isoflurane use.	C policy to ensure the	hat animals do not contact liquid	isofluorane. Please s	ee the IACUC	
post of the second seco					
C4. Describe the anesthetic gas scavenging system you will use to eliminate waste anesthetic gas. Follow the link for the policy on					
scavenging anesthetic gas.					
C5. Are any of the anesthetic or pre-anesthetic agents listed in C1 non-pharmaceutical grade? A pharmaceutical grade compound is a					
drug, biologic, or reagent that is approved by the Food and Drug Administration (FDA) or for which a chemical purity standard has been established by the <u>United States Pharmacopeia-National Formulary (USP-NF)</u> , or <u>British Pharmacopeia</u> (<u>BP</u>).					
Yes No If the answer is "yes," please explain					
US government policy requires the use of pharmaceutical grade drugs especially for anesthetics or analgesics. Exceptions include unavailability of pharmaceutical grade drug and lack of a suitable alternative. Exceptions require scientific justification.					
and tandoning of pharmacountry grade drug and lack of a suitable diternative. Exceptions require scientific justification.					

reasonable.	potential of causi	UDINGILAPAROSCOPY ngaupemanentiphysical	iorphysiologic	al handicap 🗱	
		Il recover from local or general a		<u> </u>	perative procedure.
D1. In the space	below, explain why it	is necessary for the animals to re	ecover from surgery	/anesthesia. 	
		***************************************			-
D2. In the space All anesthet	e below, describe pre- ic agents and pre-ope	operative care (including physica ative medications should be liste	il examinations, lab ed in Form C.	tests, and any precond	itioning apparatus).
D3. Use the spa	ace below to describe i	n detail the surgical procedure(s)/other major proced	dure to be used.	
Animal pre-surgi	cal preparation:				
Instrument pre-s	urgical preparation:				
Surgeon's pre-s	urgical preparation:				
Details of Techn	iques:				
surgical or other	major operative proce e and submit individual fo	assistants, and indicate the num dures to be used. Those who perform (download). Please contact Van C	orm survival surgery n	rust receive Surgery Train	ing from the Department
Name		Role in surgery	· .	Are you performing	Years of experience
				survival surgery?	with the role
	,				
	mediate postoperative <u>for the first 48 hours</u> .	care, and provide dosage, route	, and frequency of a	administration of specifi	ed analgesics (pain
Note that "A	as needed" or "PRN" do	o not constitute an acceptable sc	hedule for analgesi	a.	
Species	Analgesic Agents	Dose	Route/Vol		Frequency of Administration
			-		
			-		
				-	
Describe the im			•		·-
it is able to main	are for the animal until tain a sternal position				
(e.g., maintainin	g body temperature, ion, bandaging, vital				
signs monitoring	and monitoring				
frequency).		<u> </u>		-	

D6. List the names of individual(s)	who will check animals during recovery.
Name	AREA CODE/TELEPHONE#

D7. In the space below describe any expected or potential postoperative	e complications and describe how you will handle them.		
D8. Where will surgery/procedure be performed?	Rm		
D9. Where will animals be housed during recovery?	Rm		
D10. Where will animals be housed after recovery?	Rm		
D11. ARE MULTIPLE SURVIVAL SURGERIES PERFORMED ON THE SAME ANIMAL?			
Yes No			
D11a: Justify the need for multiple survival surgeries	-13-327		
D11b: Give the species and number of animals that will have multiple survival surgeries.			
D11c: Specify the time intervals between the surgical procedures			

EORMIE ADMINISTRATION OF SUBSTANCES ON HERTIHAN/ANEST HETICS Non Anesticité / Agents							
List all 1) Therapeutic, 2) Cell lines or Cell/Tissue extracts and 3) Other Experimental/Study non-anesthetic agents that will be administered to the animals, including but not limited to: 1) drugs such as antibiotics, analgesics or local anesthetics used to minimize post-procedural pain, distress, or discomfort, 2) isolated cells, cell lines, cell or tissue/cell extracts and 3) drugs, infectious agents such as viruses or other substances under study. For drugs under study in the experimental component of your protocol, drug type or group (e.g., non-steroidal anti-inflammatory agents, α-adrenergic receptor blockers) will suffice; however specific drugs should be indicated if known.							
E1. Therapeutic agents:			· · · · · · · · · · · · · · · · · · ·				
Species receiving the agent	Agent	Name	Dose	Route	Volume	Frequency & Total Duration	
be used in animals after co	E2. Cells or Cell/Tissue Extracts (do not include purified cell products here) Rodent cell lines, serum and cell/tissue products can only be used in animals after confirming the absence of rodent infectious agents by MAP or PCR testing. Please review the IACUC policy on cell line testing.						
Species receiving the agent	Cells or Cell/T	issue extracts	Dose	Route	Volume	Frequency and Total Duration	
agont	Name of cell line or tissue type	Species of origin		·		Duration	
		· · · · · · · · · · · · · · · · · · ·		÷			
E3. Experimental / Study A	gents						
Species receiving the agent	Agent/Subsi	tance Name	Dose Range	Route	Volume	Frequency & Total Duration	
E4. Are any of the therape	Lutic agents listed in	E1 or drugs lister	<u> </u> d in E3 are non-p	<u>l</u> harmaceutical	grade? A pha	ırmaceutical grade	
compound is a drug, biologic, or reagent that is approved by the Food and Drug Administration (FDA) or for which a chemical purity standard has been established by the United States Pharmacopeia-National Formulary (USP-NF), or British Pharmacopeia (BP).							
More information for the us							

Yes No If the answer is "yes", please explain.
US government policy requires the use of pharmaceutical grade drugs especially for anesthetics or analgesics. Exceptions include unavailability of pharmaceutical grade drug and lack of a suitable alternative. Exceptions require scientific justification.

PROLONGEDIRHYSICALIR FASTING FOODIRESTRICTION STAFFIRATHER	ESTRAINTORSTRESSORGO ANIMALS UNDER THE GARE O THANTANIMAL MEDICINE PER	NSCJOUS ANI IE TIHE INMES SONNEL	MALS IIICARORS
Complete this section if any unanesthetized anima collection, or injection. Also complete if noxious still	is will be restrained, except when the restrain	nt is for a brief exam	nination, sample
F1. Explain rationale for use of restraint or induction	n of stress:		
F2. Describe device, dimensions, etc.:			
F3. Duration and frequency animal will be confined	to device:		
F4. Observation intervals during confinement:			
F5. Qualified faculty or staff making observations:			
Name	AREA CODE/TELEPHONE#		
EG Will pain or dispended by indicado			
F6. Will pain or discomfort be induced? If yes, describe in detail using the space below	w	Yes	No
	·		
F7. Will stimulation, including light and sound, be undescribe in detail.	sed to modify animal behavior? If yes,	Yes	No
F8. Will animals be fasted (food, approx. 24 hours on a diet deficient in one or more nutrients?	and/or water, approx. 12 hours) or placed	Yes	No
If yes, provide the details below. How long animals well-being of the animal be determined How oft	s will be restricted? How will the general en will the animal be weighed?		
I have read the IACUC <u>policy on fasting</u> and agree to label all cages with start dates, stop dates, and telephone contacts.			
FQ Animal medicine staff will be restricted from	coring for animals	l Vaa	Na
F9. Animal medicine staff will be restricted from caring for animals		Yes	l ⊓
I have read the IACUC <u>policy on investiga</u> label all cages with start dates, stop dates, a Please explain why the restrictions are required be			
F10. Will analgesics, sedatives, or tranquilizers be If yes, make sure that the agent(s) are listed in		Yes	No
	-		

FORMIG HAZARDOUS AGENITINFORMATION		
Protocol may require ancillary reviews by the Institutional Biosafety Committee (IBC), the Env the Radiation Safety Office prior to the IACUC approval. IACUC will notify you if ancillary revieinformation provided in the protocol. Omission of appropriate information may delay the appropriate information may delay the approximation.	ews are required b	and Safety (EH&S), pased on the
G1. Will this project require the use of infectious biological agents? (pathogenic to man or animal) If Yes, IBC approval is required.	Yes	No D
G2. Will this project require the use of recombinant DNA technology in live animals? If Yes, IBC approval is required.	Yes	No
G3. Will this project require creation of new transgenic animals in any UMMS laboratory or transgenic core facility? If yes, IBC approval is required	Yes	No 🗆
G4. Will this project require the breeding of transgenic animals that contain transgene encoding more that 50% of the genome of an exogenous eukaryotic virus from a single family or express transgene under the control of gammaretroviral long terminal repeat? If Yes, IBC approval is required.	Yes	No 🗆
G5. Will this project require the use of materials of human origin? If Yes, IBC approval is required.	Yes	No
G6. Will this project require working with live non-human primates or materials of non-human primate origin (tissues, cells, etc.)? If Yes, IBC approval is required.	──────────────────────────────────────	L. No
G7. Will this project require the use of biotoxins? If Yes, IBC approval is required. Please see examples of biotoxins that require IBC approval:	Yes	□No
G8. Will this project require IBC approval for the use of synthetic nucleic acids (e.g. siRNA, synthetic DNA)? Please see the footnote below for synthetic nucleic acids which require IBC approval.	Yes	No □
G9. Will your research activities potentially expose humans, other than researchers and Animal Medicine personnel, to zoonotic infections (e.g., Q fever from sheep) ² ? If yes, IBC approval is required.	Yes	No
G10. Will this project require the use of ionizing radiation in live animals? If Yes, Radiation Safety approval is required	Yes	No
G11. Will this project require the use of hazardous chemicals in live animals? If Yes, Chemical Safety Review is required. Please see the footnote below for Occupational Health and Safety Administration (OSHA) definition of a hazardous chemical ³ .	∐Yes	∐№
G12. If you will be using any of the above agents, use this space to describe briefly what you version of the above agents, use this space to describe briefly what you version of the above agents, use this space to describe briefly what you version of the above agents.	will be doing.	

If the answer to ANY of the following questions is "yes," IBC approval is required for synthetic nucleic acids:

1. Will synthetic nucleic acid molecules be modified, or used in a vehicle that is intended to enhance cell membrane penetration in vivo (e.g. bound to nanoparticles)?

2. Will synthetic nucleic acid molecules have ANY of the following characteristics?

Able to express a transgene

Able to replicate in vivo

Able to integrate in cellular genome or modify genomic sequences

Prolonged (not transient) biologic effects if introduced into cells

² The researchers and Animal Medicine personnel are required to be knowledgeable about the Occupational Health and Safety hazards of the animal species they will be working with. However, if there is the possibility of untrained individuals (e.g., if animals and patients are using the same imaging equipment) contracting serious zoonotic diseases by coming into contact with animals directly or indirectly, IBC has to review and approve procedures used for transporting, experimentation, decontamination, disposal of animal waste, etc.

³ Chemical Safety Review

<u>Purpose:</u> Many chemicals used in conjunction with animals in research as part of the experimental test system have the potential to adversely affect the health and safety of researchers as well as animal care personnel. These 'hazardous chemicals' are broadly defined in the OSHA Hazard Communication Standard as chemicals that pose either a physical hazard or a health hazard to humans.

<u>Definition:</u> Among the chemicals that pose a '<u>physical hazard</u>' are those that are combustible or flammable liquids, compressed gases, organic peroxides, oxidizers, and unstable or water-reactive. Chemicals that pose a '<u>health hazard</u>' are those that may have acute or chronic health effects in exposed employees. Among these chemicals are carcinogens, toxic or highly toxic agents, reproductive toxins, sensitizers, hepatotoxins, nephrotoxins, neurotoxins, agents which act on the hematopoietic system, and agents which damage the lungs, skin, eyes, or mucous membranes. See 29 CFR

¹ Synthetic nucleic acids

1900.1200(c) for the complete definition.

<u>Process:</u> Chemicals used with animals that are considered to be potentially 'hazardous' according to OSHA need to be listed in the IACUC Animal Study Protocol application, and their use reviewed by EH&S. Material Safety Data Sheets may be consulted for guidance regarding whether or not a given chemical may pose a chemical or physical hazard to researchers and/or animal care personnel. You may contact EH&S for additional information.

G13. If you have IBC approval for the studies described in the prot information	ocol, please check the box below and fill in the requested
I (PI of this IACUC protocol) have reviewed the IBC protocol and verified that all the hazardous biological agents used in live animals under this protocol have IBC approval. There is an IBC approved animal addendum for use of animals at animal biosafety level >ABSL-1.	IBC protocol number PI of the IBC protocol

IFOIRM HE ADVERSE EFFECTISTOF PROCEDURES AND EXPERIMENTS MONITORING AND MANAGEMENT H1. What will be monitored to assess the presence of pain, discomfort, or other potential adverse effects caused by your studies? NOTE: This period includes the time from initiation of experiments until the animals are removed from the study; for surgically operated animals, this includes the time after anesthesia recovery until animals are removed from the study. Check all that apply Activity Appetite Behavior Appearance Heart rate Excreta Grooming Guarding Licking, biting Posture Respiratory rate Temperature Vocalizing Weight loss Wound site Other Laboratory tests or other evaluation (specify) H2. Indicate the frequency with which you will monitor your animals during and after all procedures. Please indicate both monitoring interval and total length of time. H3. Describe the conditions and complications that would lead to removal of an animal from the study and how this will be accomplished (e.g., stopping treatment and/or euthanasia)

	PROCEDURES	A FORN DONE IN UN	ITTI IMS:GORE4FAGILITIES
For use a UMMS core facility to protocol. However, you do not procedures are part of an IAC	for this study, you need need to list details of the UC approved core prot	to get the appro he specific proce ocol.	val for those animals used in the core facility under this dures performed in the core facility by its staff if the
I1. List below the UMMS core	facility services you wil	I be using for this	s protocol.
Name of the core facility	Name of the PI of the core facility	Protocol # (if applicable)	Briefly describe the procedures/services provided by the core facility
I2. Is any of the procedure(s) core facility personnel?			
If the answer is "Yes" please procedures under this protoco procedure(s) by core facility S	I in the core facility and	identify the	
	sed in the core facility		he IACUC approved core facility protocol, please describe
			-
I4. Use this space to describe	how you will transport	animals between	the animal facility and the study area

	FORM J ANIMAL WORK DONE OUTSIDE	UMMS	
commercial vendor. This includes being the grantee institution, is re- PHS assured institution, and appr		According to Federal	Regulations, UMMS,
J1. List below the details of anima	al work done outside UMMS		
Name of institution or company	Name of the PI or contact (if a company), & contact information (phone # or email address)	IACUC Protocol number, if applicable	Animal Species used in the study
J2. Provide a brief description of t	the animal work done at the non-UMMS site below:	r.	
		dis illument kalturannya-suoren	
UMMS IACUC may require of Evidence of collaboration or secony of the IACUC approval from IACUC. If this approval letter is Approval Letter. Evidence for PHS Assurance of will be sufficient). This is not read a copy of the protocol (translated).	cuments provided with this application. one or more of the following documents to attached between the collaborator or company indiction the non-UMMS institution to indicate that this was in a foreign language, please provide an English the of the non-UMMS institution (A copy of the Assurance equired if the Assurance number and period of validation into English, if in another language), if the collaboration in the collaboration in the protocol. In (requested by the IACUC)	icating willingness for work has been review translation along with nce Letter from NIH to dity is indicated in the	yed and approved by an a copy of the original of the institution or company a IACUC Approval Letter)

Please fill out this form, if this application is designed for training courses. The trainees should be under the sup trained UMMS investigator during any contact with live animals. Please note that the trainees are not permitted independently with live animals; to do so, they have to be listed as personnel in the protocol (please see section Federal Regulations; the IACUC is to ensure the occupational health and safety of personnel working with animing individuals working with animals receive appropriate training. Because the training participants are not known at protocol submission, IACUC recommends the following options to meet the Occupational Health and Safety and requirements, and requests that a list of participants submitted to the IACUC Office before the training session (K1. Occupational Health Evaluation of the trainees; please check all the choices that you are planning to recomparticipants. Each participant has to full fill this requirement by full filling one the choices below.	ervision of a to work h IX). According to als, and that all t the time of d Training s).
 Are the participants UMMS student, resident, employee or volunteer? Please submit an <u>Initial Health Evaluation form</u> to the Employee Health Service for obtaining Health Clearance. 	Yes No
b. Are the participants going to receive clearance for working with animals from a qualified physician? Health Clearance from a qualified physician is acceptable, if the participant is not affiliated with UMMS. The physician must review and accept the criteria established by the UMMS Occupational Health and Safety Policy. The UMMS Occupational Health and Safety Policy and Health Clearance Forms are available from the IACUC office.	Yes No
c. Are the participants going to sign the "Informed Consent Form?" (Participants who are not affiliated with UMMS) In lieu of obtaining health clearance from a qualified health care practitioner participant may submit a signed Informed Consent form indicating that they are aware of and understand the risks of working with animals . and participate at his/her own risk. This option is only allowed if the trainees are only attending one or two training session(s).	Yes No
K2. <u>Training options</u> : please check the option(s) below for participant training	·
a. Are you planning to provide an instructional lecture on working with animals? The PI or his designee can provide training in a lecture format (the lecture should include an overview of Federal Regulations, ethical guidelines for using animals, hazards and risks associated with the use of animals, species-specific information, humane techniques for animal procedures, and other appropriate information relevant to the experimental procedures being used). IACUC could provide the PIs with PowerPoint slides on the UMMS IACUC Animal Care and Use Program upon request. Please note that these slides do not cover Federal Regulations, Occupational Health Hazards and Species Specific information.	Yes No
 Are the participants UMMS students, residents, staff or volunteers? The trainees may fulfill this requirement by completing the online <u>Training courses</u> available to the New Animals Users at UMMS to meet all the training requirements. 	□ ^{Yes} □ ^{No}
K3. Are the trainees going to perform SURVIVAL SURGERY? If the trainees are going to perform survival surgery, they are required to complete <u>Survival Surgery Training</u> provided by the Dept of Animal Medicine.	Yes No

The PIs are required to provide	a list of trainees on c	or before the day of training	ing to the IACUC office. Please see next page for a
template for listing trainees. The	e list should include t	the names, affiliation and o	contact information, and evidence for completion of
the above requirements (K1 to	K3). Failure to subr	mit a list of participants r	prior to the training session may be considered a
protocol violation.			
[# 경기에 올라를 하고 있다. 경기에	为作品。13 YE Y 数4 2	하는 말다. 나를 시겠는 방법이	
店套 P. 国出来建筑的特别。第			
直接 医多数牙髓的 医肠膜炎 急			
	趣 机双环酰化二烯化		[集][[4][[4][[4][[4][[4][[4][[4][[4][[4][

TRAINING PARTICIPANT LIST (template; make additional copies if necessary)

Note: Do not have to fill this out at the time of protocol submission; to be submitted to the IACUC Office (hardcopy or pdf) on or before the day of training

PI Name:		-			<u> </u>			<u> </u>	
Docket Number:				<u> </u>					
Name of personnel conducting th other than PI: Date of training:	e training s	session if							
TRAINING PARTICIPANTS Name	Supplied to the supplied of th							and the second s	
Name	OR provid	affiliated to UMMS, de the name and of the non-UMMS affiliation	Contact information (Email and phone number)	clearance to Informed C applicable to	o work with a onsent singer	nimais. OR	Training (check applicable	box below)
				By the Employee Health Service	By a qualified physician ¹	Informed Consent Form ²	Online training courses	Classroom instruction	Surgery Training (if performing survival surgery)
	<u> </u>	<u> </u>		 -					
				 					
		<u> </u>	_	 			<u> </u>	 	
				 	<u> </u>	<u> </u>			
		<u> </u>		-			-		
		<u> </u>		 					
					<u></u>				

¹ Please submit copies of Heath Clearance certificate to the IACUC Office ² Please submit copies of the Informed Consent Form to the IACUC Office

WORKSHEET 1 (Optional)

Animal number worksheet (addendum to section IV)-add on more rows as needed Use this worksheet to show the details of animal numbers to be used for 3 years

Species -----(please use one sheet/species) В D G Е Н # Experiment or procedure1 Number Number of Total Estimated Total number Source of animals Pain level of groups, number of number of of animals animals includina animals per additional requested To be transferred from another protocol Ε replicates experi-ment animals to (Sum of E group² and F) compen-To be purchased To be bred procedure sate for possible. death or protocol Grand total

¹The specific experiment(s) and procedure(s) listed here should be referenced in the Experimental Design (section IV)

² Should be based on justification (power analysis, previous publications, etc.) for the number of animals as described in section IV

WORKSHEET 2 (Optional)

Breeding worksheet (add more rows if needed)

Α_		В		C	D	E	F	G	Н		J
#	Animal strain, genotype, phenotype, etc.		Number of animals from outside	Number of matings	Expected litter size	Total number of pups expected	Number of pups expected to	Number of pups which may not be	Number of pups to be used for	Total number of animals (sum of	
	Offspring	Parents		source used in mating ¹				be used in experiments	may not be used in experiments	continued breeding	columns C and F)
										_	
_					<u> </u>		<u> </u>	<u> </u>			_
				-							
											
								<u></u>		-	
4											
4											
\exists											
+					-				_		
									_		
irai	nd total				Not applic	able					<u> </u>

¹ Animals purchased or obtained from other investigators used in breeding, do not use animals bred in house used for breeding in this column

3b. Protocol

UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL	
ANIMAL CARE AND USE COMMITTEE	
Animal Study Protocol	

PI Name:	Docket Number: A-
PART 1: ADMINISTRATIVE QUESTIONS	
1.0 Study Type*	□ New
	☐ 3-Year
	☐ Amendment (summarize below)
1.1 Docket #	
1.2 PI Name *	
1.3 Faculty Title *	Choose an item.
If "other" describe:	Choose an item.
1.4 Email Address *	
1.5 Phone Number *	
Telephone type	□ OFFICE →□ CELL □ OTHER
1.6 Academic Degree *	Choose a degree
	5.10038
1.7 Department/Division or Company Name *	Select a Department.
1.8 Emergency Phone Number *	
1.9 Faculty Sponsor (if required)	
1.10 Co-investigator	
1.11 Primary Contact Person *	
1.12 Primary Contact Email *	
1.13 Primary Contact Phone Number *	
1.14 Project Title *	

1.15 Grants Associated with this Animal Pro	otocol	· -			
Grant Sponsor	Grai	nt ID		Grant PI	
Choose an item.					
Choose an item.					
Choose an item.					
Choose an item.					
1.16 Has the study undergone peer-review	? *	☐ YES	□ NO		



2.1 Lay summary: Briefly summarize the background and goals of your animal studies using non-technical terms that could be understood by individuals with high school level education. *				
,				
2.2 Scientific Summary: Briefly describe the specific aims and procedures should not be entered here. This section will help your study. The IACUC does not use this section to conduct a	the committee underst	and the rationale and goals of		
2.3 Describe the potential scientific benefit of the proposed s scientific knowledge, or the good of society. *	tudy to human or anima	al health, the advancement of		
2.4 Dates of Searches: Years covered by the search (From - To) *	From: -select date-	To: -select date-		
2.5 Keywords searched: Keywords must include procedures t distress. If not enter N/A. *	hat may generate more	than momentary pain or		
2.6 Databases searched to determine:	*□ PubMed/Medline			
 That you are not unnecessarily duplicating previous experiments, that alternatives to animal use are either not available or not appropriate, that procedures involving animals will avoid or minimize discomfort, distress and pain, AND that alternatives to procedures that may cause more than momentary or slight pain or distress have been considered. 	* Scopus * Web of Science * Agricola * AltWeb * Animal Welfare In * UMMS Veterinaria			
2.7 Did the search identify less painful alternatives, previous studies that would be unnecessarily duplicated or alternative approaches that would not require animals? * 2.8 If you answered YES to the above question, please explain	☐ YES ☐ NO n why the proposed stud	dies are required.		



2.9 Why are vertebrate animals required for your study? *
* The complexity of the processes being studied cannot be duplicated or modeled in simpler systems
* There is not enough information known about the processes being studied
*□ Preclinical studies in living animals are necessary prior to human testing.
*□ This is a behavioral, learning or developmental study
*□ Other. Please explain:
2.10 Why are the proposed species the most appropriate for your studies? Check all that apply. *
* The anatomy, genetics, physiology or behavior of this species is uniquely suited to the study.
*□ This is the phylogentically lowest species that provides adequate size, tissue, or anatomy.
* This species provides a particularly good model for duplicating the human situation.
* Previous studies using this species formed the background of this project.
* This species has the following unique features that make it the best choice available for this study.
*□ Other. Please explain:
2.11. Briefly explain your selection(s) from 2.10.*



PART 3: EXPERIMENTAL DESIG	GN				,
 3.1 List the number of animals you will use over the duration (to a maximum of 3 years) of this protocol. Include mouse and rat fetuses ≥17 days of gestation. The total should include all animals bred for use in experiments AND all animals generated by breeding that are discarded due to the wrong genotype and/or sex. Pain/distress level indicates maximum pain or distress level to be experienced by animals: B=USDA covered species only being bred but not used in testing, teaching or experiments (do not include mice/rats) C=negligible pain/distress 					
D=pain/distress relievedE=pain/distress not relie					
Species	Category B	Category C	Category D	Category E	Total
Choose species.					
Choose species.					
Choose species.					
Choose species.					
Choose species.					
Choose species.					
Note: This table will not automat	ically total colum	ns. Please ente	r the total for e	ach row.	
3.2 Category E Justification: If you have animals in category E, briefly refer to the procedures producing pain or distress and/or a timeline of disease progression, and list the reasons why pain-relieving drugs cannot or will not be used to relieve pain or distress. If pain/distress relief would interfere with test results, justify why that is true.					
3.3 Are you planning to reuse animals that were previously used for other experiments or procedures under a different protocol? *					
3.4 If the answer is "yes" to question 3.3 please provide more details (number of animals, what previous procedures done in these animals)					
3.5 If there are federal guidelines or regulations that require the use of laboratory animals then please cite the agency, CFR title, number and specific section (e.g., Food and Drug Administration, 21:CFR 1030.110).					
3.6 The number of animals re	•				nber required to achieve
protocol is based on the following. Guidance on statistical significance animal number justification can be found on the					
UMMS IACUC web site. (select all that apply) *					



	*□ The number necessary to obtain sufficient tissue or other material for testing or analysis
	*□ The number required to provide sufficient technical training or practice for the number of trainees expected
	* The expected or established mortality associated with this procedure
	* The number of animals generated from breeding that cannot be used due to the wrong genotype or gender
•	*□ Other (<i>explain below</i>)
2.6.a. Please provide details of the number of ani	mals requested based on experimental design, including the
	per group. Be sure that the total number of animals based on
experimental design match the total # of animals	- •
3.7 Write a brief description of experimental designation animals from initial contact to euthanasia *	gn using a chronological list of activities to be carried out on living
3.8 If using an approved standard procedure	*□ Facial Vein Blood Collection
from the UMMS IACUC website without modification please check the appropriate check	*□ Lateral Tail Vein Blood Collection
box (s) below. Deviations to standard	*□ Retro-Orbital Bleeding
procedures should be described in section 3.10.	*□ Use of Freund's Complete Adjuvant (FCA)
	* Ascites Production for Monoclonal Antibodies
	*□ Tail Snipping of Mice up to 21 days of age
·	*□ Tail Snipping of Mice between 22-28 days of age
	*□ Tail Snipping of Mice > 28 days of age
	* Ear Punching as Alternative to Tail Snipping for Isolating DNA
	*□ Intramuscular injections in rabbit
·	* Pearl Imaging
	I *□ IVIS Imaging
	*□ IVIS Imaging



below.	SS Research Core Facility please check the appropriate check box(s)					
If procedures and/or species are not covered und procedures for each species in narrative form in	der the core protocol(s) please provide a detailed description of the section 3.10.					
*□ Advanced MRI Core						
*□ Transgenic Animal Modeling Core						
*□ Metabolism Core						
*□ Micro CT						
*□ Radio Labeling Small Animal Translational Im	naging Core					
3.10 Please provide a detailed description of the procedures for each species in narrative form. Do not include procedures done post mortem. Do not include survival surgery. Please use Form D to describe details of survival surgical procedures.						
2.11 Indicate house, will it will be a few or a few of the few of						
3.11 Indicate how you will identify animals. *	*□ Animal identification is not necessary for this protocol. Cage cards will be used.					
	*□ Ear tagging/notching					
	*□ Tattoo					
•	*□ Dye or ink marking					
	*□ SQ radio					
	*□ Tag (microchip)					
•	*□ Vendor-placed tag or tattoo					
	*□ Other					
[If "Other" is selected in 3.11, please explain the						
	y or care that animals may need. Check all that apply.					
Please provide a description and justification for						
*□ Single housing for social species. Provide a description and justification below.						



*☐ Cage density exceeding limit. Provide a descrip	otion and justification below.			
*□ Modified Cogo shapes for a constant of	vovido o dossistico oud instification hala			
*□ Modified Cage change frequency exception. Pr	rovide a description and justification below.			
*□ Animal husbandry done by research staff. Prov	vide a description and justification below.			
*□ Deviation from standard housing condition (codescription and justification below.	old exposure, light/dark cycle, standard enrichment plan). Provide a			
*□ Food/water manipulation (e.g. Medicated foo	d and/or water, increase/decrease food, special diet)			
*□ Other: Please describe and provide a justification below.				
3.13 Is death used as an endpoint in this study? *	□ YES □NO			
3.14 If you answered "YES" to 3.13, explain why an earlier end point is not acceptable. (Studies using death as an endpoint are Category E)				
3.15 Will there be the presence of pain, discomfort, or other adverse events caused by disease models, surgery, or other procedures used in your studies? *				
3.16 If you answered "YES" to 3.15, please indicate	e what will be monitored. Check all that apply.			
*□ Activity	*□ Licking, biting			
*□ Appearance	*□ Posture			
*□ Appetite *□ Respiratory rate				
*□ Behavior	* Temperature			



*□ Excreta			*□ Vocal	lizing		
*□ Grooming	*□ Grooming			*□ Weight loss		
*□ Guarding			*□ Wound site			
*□ Heart rate			 *□ Othe	r (describe below)		
				,		
describe frequency	of monitoring during ngoing monitoring w	g disease p	rogression	or procedures causing	essful procedures. Please pain or distress (written Do not include post-operative	
3.18 What criteria w complications that v	· ·			than planned? Please i the study.	nclude conditions and	
euthanizing animals species in the most	ecified by the princi on behalf of the pri recent edition of the	pal investi ncipal inve e euthanas	igator, Dep estigator w sia guidelin	artment of Animal Med ill do so using any meth es of the American Veto	licine personnel who are nod listed as acceptable for the erinary Medical Association.	
Neonatal and pregn	ant rats and mice wi	ill be euth	anized usin	g methods approved b	y the UMMS IACUC.	
Species	Primary Method	Dose	Route	Secondary Method	Comments	
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary		-	Select Secondary		
Select Species	Select Primary			Select Secondary		
Select Species	Select Primary	1		Select Secondary		
Select Species	Select Primary	 	+	Select Secondary		



FORM A: TRANSPORTING ANIMALS FOR USE OUTSIDE OF OR TO ANOTHER AREA OF THE ANIMAL FACILITIES						
A1 Will animals be used in areas, e.g. laboratories, outside one of the general animal facilities? *			☐ YES ☐ſ	NO		
A2 If you answered yes t animal facility. Please ch (mice and rats) or 12 ho	eck 'yes' for e	xtended housing if a	* *			
Building	Room #	Species	Survivat Surgery	Terminal Surgery	Non- Surgical Procedure	Extended Housing
Choose location			□ YES □ NO	□ YES □ NO	□ YES □ NO	□ YES □ NO
Choose location			☐ YES ☐ NO	□ YES □ NO	□ YES □ NO	□ YES □ NO
Choose location			☐ YES ☐ NO	□ YES □ NO	☐ YES ☐ NO	□ YES □ NO
Choose location			☐ YES ☐ NO	□ YES □ NO	☐ YES ☐ NO	☐ YES ☐ NO
Choose location			☐ YES ☐ NO	☐ YES ☐ NO	□ YES □ NO	□ YES □ NO
A3 If animals will be held, housed and/or used in an area outside of the animal facility for an extended period of time, please describe the duration and reason.						
A4 How will you transport animals from the animal facility to a study area outside of the animal facility? *						
A5 When moving animals from one Department of Animal Medicine managed housing room to a different animal housing room, do you agree to use the Web Animal Ordering System. *						



FORM B: BREEDING	FORM B: BREEDING				
B1 How many animals do you expect to breed for each spe	cies? *				
Species	Number of animals to be breed				
B2 Male / Female standard ratio: check all that apply *	*□ a ratio of 1:1 will be used. No continuous breeding.				
be water remaie standard rado. Check all that apply	_				
	*□ a ratio of 1:1 with continuous breeding will be used.				
	*□ a ratio of 1:2 or 1:3 will be used (Harem breeding).				
	*□ Non-standard ratio				
B3 Explain non-standard ratios:					
B4 I have read the IACUC Mouse Breeding Policy that	☐ YES ☐ NO				
prohibits more than one litter per cage. I agree to separate pregnant females to other cages prior to their					
giving birth in harem breeding and to wean continuously					
bred litters at day 21 if the female is pregnant. *					
B5 At what age will the offspring be weaned (if applicable)	?*				
B6 Please justify exceptions to the IACUC policies on roder	nt breeding and overcrowding.				



FORM C: ANESTHESIA A	ND ANALGES!	A					
C1 Pre-anesthetic Agent			-			e refer to I/	ACUC website for
specific policies on the u	use of ketamin	e/xylazine, i	isofluorane	or averti	n.		
Species	Agent	Dose	Rou	te	Frequency & Duration		Procedure
			<u> </u>				
<u>. </u>					- <u></u>		
·					<u>.</u> .		
C2 Please describe seco	ndary anesthe	tic dosing, i	f applicable	e.			
C3 If anesthetizing anim	vale with icoflu	rano ucina t	ho onon	- Vec	Пио		·
drop method, will IACU				│ □ YES	□ NO		·
Isoflurane: drop metho		7 7		!			
C4 List any non-pharma	_	anesthetic	or pre-	☐ YES	□NO	□NA	
anesthetic agents listed	l in C1.			[
· · · · · · · · · · · · · · · · · · ·		•					
C5 If using non-pharma	_	anesthetics	or pre-	☐ YES	□ NO	□ NA	
anesthetic agents, plea	se justify						
C6 I agree to follow IAC		-	-	☐ YE\$	□ NO		
storage of drugs/chemi	· · · · · · · · · · · · · · · · · · ·		•				
C7 Monitoring of Anest monitored.	hesia: Describe	e what will i	be	1	oebral reflex		
monitorea.				* □Hea	rt rate		
				* □Res	piration		
				* □Temperature			



			*	☐Toe Pinch		
			k	□Other: describe be	elow	
		·,	<u> </u>			
escribe how frequ	ently each of th	he signs listed	in C7 will b	e monitored.		
						,
Describe the anesthetic gas scavenging system you will to eliminate waste anesthetic gas.				☐Building vacuum s	ystem	
				□Non-recirculating	fume hoo	d or externally hard
			ŀ	ucted hood		
				□Activated charcoal		s (e.g. F/air canister
			*	□Other: describe be	low	
Please describe an	algesic agents ((must be USP	grade).			
Please describe an Species	algesic agents (must be USP	grade).	Frequency & Duration		Procedure
						Procedure
						Procedure
						Procedure
						Procedure
						Procedure
						Procedure
						Procedure
						Procedure
						Procedure



FORM D: SURVIVAL SURGERY INCLUDING LAPAROSCOPY,	, ENDOSCO	PY					
(and any procedure that has a reasonable potential of causing a permanent physical or physiological handicap.)							
D1 Explain why it is necessary for the animals to recover from surgery/anesthesia. *							
D2 Describe pre-operative care (including physical examination	•						
All anesthetic agents and pre-operative medications shoul	d be listed i	In Form C. *					
D3 Animal pre-surgical preparation. If using small	TUVES	Пио					
animals, will you follow pre-surgical animal preparation	│ □ YES	□NO					
as described in IACUC policy 6.12 for Basic Survival							
Surgical Preparation? If no, please describe. *	<u> </u>						
							
D4 Instrument pre-surgical preparation. If using small animals, will you follow pre-surgical instrument	☐ YES	□NO					
preparation as described in IACUC policy 6.10 for							
Autoclave Sterilization of Surgical Instruments? If no,							
please describe. *							
*							
D5 Surgeon's pre-surgical preparation. If using small	☐ YES	□NO					
animals, will you follow pre-surgical surgeon preparation		LNO					
as described in IACUC policy 6.12 for Basic Survival							
Surgical Preparation? If no, please describe. *							
D6 Describe each surgical procedure in detail. *							
Do Describe each surgical procedure in detail.							



	
D7 Describe post-operative monitoring until fully recove	red. *
, , ,	
D8 Describe any expected or potential post-operative co	mplications. *
	·
	· · · · · · · · · · · · · · · · · · ·
D9 Will animals undergo more than a single survival	□ YES □ NO
surgical procedure? If yes, please explain. *	
1	



Biologics: Cells or Cell/Tissue Extracts or Blood Products (do not include purified cell products here).							
Agent	Species of Origin	Species	Dose	Volume	Route	Frequency & Duration	
				1			



E2 Agents/Drugs (exc	luding analgesics ar	nd anesthetics	s)			
Agent	Species	Dose	Volume	Route	Frequency Duration	USP (Y/N)
	-					
				:		
		<u> </u>				
	-					
E3 Rodent-derived m pathogens prior to using rodent-derived pathogen testing res	se according to UM I materials, do you :	MS policy. If	☐ YES	□ NO □ N	/A	
E4 Please justify use of non-USP grade for agents listed:				is not available er: describe belo	in suitable formulati ow	on
E5 I agree to follow I storage of drugs/che			d 🗆 YES	□NO		



FORM F: PROLONGED PHYSICAL RESTRAINT OR STRESS OF	CONSCIOUS ANIMALS
F1 Will animals undergo: *	*□ Prolonged physical restraint of conscious animals beyond routine handling
	*□ Electric Shock
	*□ Other: describe below
[7] 14/L	
F2 Why are restraints or adverse conditions required? *	
F3 Describe condition(s) and/or device: *	
F4 For animals confined to a device, please describe the du	ration and frequency animals will be confined. Please
include how the general well-being of the animals will be d	
F5 For animals confined to a restraint device, describe the	acclimation to device, if applicable.



FORM G: HAZARDOUS AGENT INFORMATION		
G1.a Will this project require the use of any of the following agents in live animals:		
G1.a Infectious biological agents (pathogenic to man or animal)? *	☐ YES	□ NO
G1.b Recombinant nucleic acids (e.g., recombinant plasmids, lentivirus, adenovirus, AAV)? *	☐ YES	□ NO
G1.c Synthetic nucleic acids? *	☐ YES	□ NO
G1.d Materials of human origin (tissues, cells, etc.)? *	☐ YES	□ NO
G1.e Materials of non-human primate origin (tissues, cells, etc.)? *	☐ YES	□ NO
G1.f Biotoxins (e.g., LPS)? *	☐ YES	□NO
G2 List below the hazardous agents that require housing of animals in animal biocontainment the IBC-approved animal addendum. These agents must also be listed in form E.	ABSL-2 or A	ABSL-3 per
G3 Will this project require creation of new transgenic, knockout, knock-in or other mutations in the genome of animals in any UMMS laboratory or transgenic core facility? *	☐ YES	□NO
G4 Will this project require the breeding of transgenic animals that contain transgene encoding more that 50% of the genome of an exogenous eukaryotic virus from a single family or express transgene under the control of gammaretroviral long terminal repeat? *	☐ YES	□NO
G5 Will your research activities potentially expose humans, other than researchers and Animal Medicine personnel who are already trained, to zoonotic infections (e.g., Q fever from sheep)? *	☐ YES	□NO
G6 If checked yes to G3-G5, please describe briefly		
G7 Will your research involve working with nonhuman primates? *	☐ YES	□ NO
G8 If you have IBC approval for the studies described in this protocol please fill in the requeste NOTE: Only individuals listed and approved in the IBC and IACUC protocols are authorized to work with agents in live animals.		
G8.a IBC protocol number		
G8.b Principle Investigator of the IBC protocol		
G9 Will this project require the use of ionizing radiation in live animals? If Yes, Radiation Safety approval is required*	☐ YES	□NO
G10 If checked "yes" for G9, identify the name of the agent(s) below	<u> </u>	
G11 Will this project require the use of hazardous chemicals in live animals? *	□YES	□NO



G12 If checked "yes" for G11, identify the name of the agent(s) below	



FORM H: USE OF ANIMALS IN A TRAINING COURSE

This form is designed for PIs conducting training courses. Training participants are not permitted to work independently with live animals and must be under the supervision of a trained UMMS investigator during any contact with live animals. According to federal regulations, the IACUC must ensure the occupational health and safety of all individuals working with animals, and that all individuals working with animals receive appropriate training. Because the training participants may not be known at the time of protocol submission, the PI must provide assurance that Occupational Health and Safety and training requirements will be met before trainees participate in the course. Below outlines requirements for participants.

FOR PARTICIPANTS <u>AFFILIATED</u> WITH UMMS (students, residents, employees or volunteers must complete the following requirements before beginning the course):

- 1. Occupational Health and Safety Requirements: health clearance by Employee Health Services. An initial health clearance form must be submitted to Employee Health Services and approved before participating in the course.
- 2. **Regulatory training requirements:** Training through the AALAS Learning Library: Module 1, Module 2 and species-specific training. Information on accessing the AALAS Learning Library is available on the IACUC website.
- 3. Submission of an amendment to add the participant and an approval letter from the IACUC Office.

FOR PARTICIPANTS NOT AFFILIATED WITH UMMS:

1. Occupational Health and Safety Requirements:

- If the participant is <u>NOT</u> a UMMS student, resident, employee or volunteer, Initial Health Clearance and Visiting Researcher forms may be submitted to Employee Health Services.
- If trainees are only attending a single training session, in lieu of obtaining health clearance, the participant may submit a signed Informed Consent form indicating they are aware of and understand the risks of working with animals and agreeing to participate at his/her own risk. The PI is required to submit the consent forms to the IACUC office along with the participant roster.

2. Regulatory training requirements:

- Training through the AALAS Learning Library: Module 1, Module 2 and species-specific training.
 Information on accessing the AALAS Learning Library is available on the IACUC website.
- In lieu of the AALAS Learning Library, the PI or his designee can provide training in a lecture format
 (the lecture should include an overview of Federal Regulations, ethical guidelines for using animals,
 hazards and risks associated with the use of animals, species-specific information, humane
 techniques for animal procedures, and other appropriate information relevant to the experimental
 procedures being used)
- 3. Submission of the participant roster (below) to the IACUC office, as training sessions occur, including the name of participants and method of health clearance for each individual.



Participant Name	Date of Training Course	Health Clearance	Regulatory Training
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library
		☐ Informed Consent	☐ Instructional lecture
		☐ Health Clearance from EHS	☐ AALAS Learning Library



PART 5: PARTICIPATING PERSONNEL

First	Last	Phone	Emergency Phone	Responsibilities	Years experience with technique	Years experience with species	First time user (Y/N)

Briefly describe how the individuals with less than one year of experience with the technique(s) in species will be trained and/or supervised. Identify the individual(s) who would be responsible for training and/or supervising new or inexperienced personnel. Note that hands-on training can be given by an experienced personnel or designated Department of Animal Medicine staff. Those who perform survival surgery must receive aseptic Survival Surgery Training from the Department of Animal Medicine before approved as a surgeon. Please contact Van Gould (extension 66811) or Suzanne Wheeler (extension 62363) for training.

ADDITIONAL NOTES ON PARTICIPATING PERSONNEL:

IACUC training webpage | IACUC new personnel webpage

- Before other new personnel perform any procedures, a written minor amendment request must be submitted to and approved by the IACUC. All personnel new to UMMS or those who never worked with animals will have to complete all the Training and Occupational Health and Safety Requirements before added on an IACUC protocol.
- The principal investigator is responsible for ensuring that all personnel adhere to the conditions approved by the IACUC.



APPLICANT'S CERTIFICATION

IACUC is charged with carrying out the rules and regulations of the Federal Government's Animal Welfare Act governing the care and use of animals in research and instruction. The Act stipulates that (a) Principal Investigators must give written assurance that the activities do not unnecessarily duplicate previous experiments; (b) procedures involving animals must avoid or minimize discomfort, distress, and pain to the animals; (c) Principal Investigators must consider alternatives to procedures that cause more than momentary or slight pain or distress to the animals and give a written description of methods used to determine that alternatives are not available; and (d) paralytic agents cannot be used in unanesthetized animals. Accordingly, the Applicant, who must be a member of the faculty holding Principal Investigator status, is required to read and sign the following certification:

BY SIGNING BELOW, I CERTIFY THE FOLLOWING:

- 1. I am thoroughly familiar with the literature in the field of research proposed in this application, and I have determined that the research does not unnecessarily duplicate experiments, that appropriate non-animal models are not available, and that the research must be conducted on living animals.
- 2. I will abide by all UMMS policies and procedures regulating use of animals in instruction and research, by the provisions of the PHS/NIH Guide for the Care and Use of Laboratory Animals, and by all other applicable laws, policies, and regulations governing the use of animals in instruction and research.
- 3. I will supervise all experiments involving live animals. Furthermore, I will ensure that all listed participants are qualified or will be trained in proper procedures, including animal handling, anesthesia, surgery, post-procedural management, and euthanasia. Also, I will ensure that individuals not listed in the application will not have responsibility in experiments involving animals.
- 4. All listed personnel will read the IACUC-approved Application to Use Vertebrate Animals in Research or Instruction before undertaking any procedures on laboratory animals.
- 5. Survival surgery will be performed using standard aseptic procedures.
- 6. Animal Medicine clinical veterinary staff will be consulted as needed to ensure satisfactory veterinary care.
- 7. In the event of an animal health emergency, my staff or I will contact the Department of Animal Medicine. We will not attempt animal treatment by ourselves, unless it is a life-threatening emergency.
- 8. If I cannot be contacted, and animals in this project show evidence of illness or pain, emergency care, including euthanasia, may be administered at the discretion of the Animal Medicine veterinary staff.
- 9. Significant changes in study objectives and procedures require IACUC approval.
- 10. Unanticipated adverse events will be reported to the IACUC as required by UMMS IACUC policy
- 11. This application meets all animal use and care requirements of the funding agencies that have been asked to support the research.
- 12. By signing below, I certify that all animal studies described in grant proposals using this protocol are described in this animal use application.

PI's Signature:	Date:

3c. Protocol

Print: PROTO201900283 - Blank Protocol



Print

Close

View: SF: Basic Information

Basic Information

	1.	*	Se	lect	resea	rch	team
--	----	---	----	------	-------	-----	------

2. *Title of protocol:

3. * Short title:

4. Summary of research:

5. Principal investigator:

6. What is the intention of the animal protocol?

×

View: SF: Experimental Research Protocol Addition

Experimental Research Protocol Addition

1. * Will the protocol include breeding?

• Yes O No

View: SF: Protocol Team Members

Protocol Team Members

1. Identify each additional person involved in the design, conduct, or reporting of the research:

2. External team member information:

View: SF: Funding Sources

Funding Sources

1. Identify each organization supplying funding for the protocol:

Funding Sponsor's Funding Grants Office Documents Organization ID ID

2. Indicate the protocol team members who have a financial interest in this research:

View: SF: Scientific Aims

Scientific Aims

4	J.	~ ·	•	4 * *	•	•		4.0			
٠,	π.	SOL	Δn	TIT	10	aime	L OT	tno	resea	ואיוו	n
		~~				anni			10300		

2. * Significance and benefits of the research:

View: SF: Experiments_custom

Experiments

1. * Define the experiments to be used in this protocol:

Name Species USDA Count	Count by Pain Category	Common Procedures	Variable Procedures	Variable Description
	B: 0		·	
	C: 0			
	D: 0			
	E: 0			

- 2. If the experiments include survival surgery, will any single animal undergo more than one survival surgery? (include any animal that underwent surgery prior to use on this protocol)
- 3. *Describe the order of and time interval between surgical procedures on a single animal:
 - * Provide scientific justification for multiple survival surgical procedures on a single animal:
 - * Specify how many animals will undergo multiple survival surgeries:

View: SF: Procedure Personnel Assignment_custom

Procedure Personnel Assignment

- Describe a training plan for research team members with less than 1 year of species-specific experience with a procedure(s).
 Training records must be maintained by the laboratory to document completion of training:
- 2. * Select the team members who will be performing each procedure:

Procedure Species USDA Species Members

^	_		4
ა.	Team	member	training:

First Name Last Name Training Course Category Source Stage Completion date Experience

View: SF: Strains_custom

Strains

1. Identify strains or genotypes associated with this protocol that are expected to have a phenotype(s) adversely affecting animal health and/or welfare:							
	Species	Is USDA Species	Strain	Genetically Modified Strain	Phenotype		
Identify strains or genotypes associated with this protocol that are expected to have a phenotype(s) adversely affecting animal health and/or welfare:							
2. Species:							
3.* Genetically modified strain:							
4. Phenotype:							
5. Percent of animals with the phenotype:							
6.	6. Describe the management plan for these animals, including any supportive care to be provided:						

View: SF: Animal Justification_custom

Animal Justification

protocol as needed:	animais to i	oe usea or produced	tor this				
Species USDA Covered Species	Pain Category	Animals Identified in Experiments	Adjusted Animal Count				
	Pain Category B						
	Pain Category C						
	Pain Category D						
	Pain Category E						
2. If you adjusted the number of animals for this protocol, explain why:							
3. * Provide the rationale for using animals in this protocol:							
4. * Justify why each proposed species was chosen for this protocol:							
5. Identify each source of animals for this protocol:							
6. Supporting document	s:						
Document Name Date Modified							

View: SF: Alternatives and Duplication Searches

Alternatives and Duplication Searches

Aite	manves	ma Dupneano	ii Searches				
	ecord all searcl ght duplicate:	nes for any previous i	esearch that this protocol				
	Search Date	Searched Databases	Keywords				
Viev	v						
b. c. d. e.		plicates Summary:					
2. Identify any other references used to find alternatives: (such as periodicals, publications and consultation)							
	_	ave made every effor duplication of previo	t to ensure that this protocol ous research: □				

View: SF: Breeding_custom

Breeding

- 1. * Describe the objectives and justifications for this breeding activity:
- 2. * Describe the methods you will use to identify the offspring:
- 3. Identify any other protocols to which you will supply animals bred from this protocol:

View: SF: Housing and Use Custom

Housing and Use

1. Identify each non-vivarium location where animals will be housed or used:

Name			Species Hours		Reason	
					•	
Vie	ew					

Sub questions:

- a. Identify the location where animals will be housed or used outside the vivarium:
- b. What species will be housed or used in this location?
- c. How many hours will animals be kept:
- d. Describe how this location will be used:
- e. Justify why the animals must be removed from the vivarium:
- f. Described how animals will be transported to and from this location, including container and route:

View: SF: Disposition

Disposition

- 1. Disposition plans for the animals when this research is complete: (check all that apply)
- 2. If other, provide an animal disposition description:

View: SF: Custom_Other Information

Other Information

1. IBC Registration Number:

Procedures Appendix:



View: SF: Procedure Identification_custom

Procedure Identification

- : Core Procedure
 - 1. * Name of the procedure or surgery:

Core Procedure

- 2. * Select procedure type: Core Procedure
- 3. * Species:
- 4. * Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

- i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):
- ii. Identify criteria under which animals will be removed from research:

View: SF: Core Procedures_custom

Core Procedures

1. List the procedure(s) being performed by the core (detailed description is not required):



View: SF: Procedure Identification_custom

Procedure Identification

- : Euthanasia Procedure
 - 1. * Name of the procedure or surgery:

Euthanasia Procedure

- 2. * Select procedure type: Euthanasia
- 3. * Species:
- 4. * Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

- i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):
- ii. Identify criteria under which animals will be removed from research:

View: SF: Euthanasia

Euthanasia

- 1. * Method of euthanasia:
- 2. Describe procedure:
- 3. Describe how death will be confirmed:
- 4. If animals will be anesthetized prior to euthanasia, select the anesthesia procedures to be used:

There are no items to display

Alternatively, if you cannot find the procedures in the list above, enter the information here:

Describe each substance and the step-by-step procedure to be used: (include route, dose, volume, concentration, and whether substance is pharmaceutical grade)



View: SF: Procedure Identification_custom

Procedure Identification

	T) 1	• 1	T 1
٠	RAK	ากรบเกษกโ	Propoduro
•	DCI	iaviorai	Procedure

1. *Name of the procedure or surgery:

Behavioral Procedure

- 2. *Select procedure type: Behavioral
- 3. *Species:
- 4. *Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

- i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):
- ii. Identify criteria under which animals will be removed from research:

View: SF: Behavioral Procedures_custom

Behavioral Procedures

 *Describe the procedure, 	including	length	and frequency of
sessions:			

- 2. Describe any apparatus you will use, and provide the details of sanitation between uses:
- 3. Indicate how animals will be monitored for stress during the procedure, include any criteria for prematurely ending the session:
- 4. Select the anesthesia and analgesia procedures to be used:

Name

Type

Version

Scope

There are no items to display

Alternatively, if you cannot find the procedures in the list above, enter the information here:

Describe each substance and the step-by-step procedure to be used: (include route, dose, volume, concentration, and whether substance is pharmaceutical grade)

- 5. Describe the anesthetic monitoring:
- 6. Describe post-procedural care and monitoring:



View: SF: Procedure Identification_custom

Procedure Identification

- : Antibody production procedure
 - 1. *Name of the procedure or surgery:
 - 2. *Select procedure type: Antibody Production
 - 3. *Species:
 - 4. * Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

- i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):
- ii. Identify criteria under which animals will be removed from research:

View: SF: Antibody Production_custom

Antibody Production

1. *Describe the procedure:	

- 2. *Justify the use of live animals for antibody production: *
- 3. Describe your plans to monitor and alleviate pain:

4. Select the anesthesia and analgesia procedures to be used:

Name Type Version Scope
There are no items to display

Alternatively, if you cannot find the procedures in the list above, enter the information here:

Describe each substance and the step-by-step procedure to be used: (include route, dose, volume, concentration, and whether substance is pharmaceutical grade)

- 5. Describe the anesthetic monitoring:
- 6. Describe post-procedural care and monitoring:



View: SF: Procedure Identification_custom

Procedure Identification

- : Non-survival Surgery Procedure
 - 1. *Name of the procedure or surgery:
 Blank Non-survival Surgery Procedure
 - 2. *Select procedure type: Non-Survival Surgery
 - 3. *Species:
 - 4. *Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

- i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):
- ii. Identify criteria under which animals will be removed from research:

View: SF: Non-Survival Surgery

Non-Survival Surgery

- 1. *Describe the surgical procedure:
- 2. *Describe how the animal, surgeon, and instruments will be prepared for surgery:
- 3. Describe how death will be confirmed:
- 4. Select the anesthesia and analgesia procedures to be used:

 There are no items to display

Alternatively, if you cannot find the procedures in the list above, enter the information here:

Describe each substance and the step-by-step procedure to be used: (include route, dose, volume, concentration, and whether substance is pharmaceutical grade)

5. Describe the anesthetic monitoring:



View: SF: Procedure Identification_custom

Procedure Identification

- : Blank Imaging Procedure
 - 1. *Name of the procedure or surgery: Imaging Procedure
 - 2. * Select procedure type: Imaging
 - 3. * Species:
 - 4. * Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

- i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):
- ii. Identify criteria under which animals will be removed from research:

View: SF: Imaging_custom

T '	
IMAGGINA	•
Imaging	,
	_
· ·	,

1.	1. Imaging types:							
2.	2. Frequency:							
3.	3. Duration of imaging session:							
4.	. Purpose:							
5.	. Will supportiv Yes No	ve care of	animals be nec	essary?				
6.	. If yes, descrik	be:						
7.	. Select the and	esthesia a	ınd analgesia pr	ocedures to be used:				
		Туре	Version	Scope				
	There are no item			Ссорс				
	information	here:		res in the list above, enter the				
	Describe each substance and the step-by-step procedure to be used: (include route, dose, volume, concentration, and whether substance is pharmaceutical grade)							
8.	. Describe the	anestheti	c monitoring:					
9.	. Describe pos	t-procedu	ral care and mo	nitoring:				

View: SF: Procedure Identification_custom

Procedure Identification

- : Breeding Procedure
- 1. *Name of the procedure or surgery:
 Breeding Procedure
- 2. *Select procedure type: Breeding
- 3. *Species:
- 4. * Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

- i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):
- ii. Identify criteria under which animals will be removed from research:

View: SF: Procedure Identification_custom

Procedure Identification

- : Survival Surgery Procedure
 - 1. * Name of the procedure or surgery: Survival Surgery Procedure
 - 2. *Select procedure type: Survival Surgery
 - 3. *Species:
 - 4. *Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):

View: SF: Survival Surgery_custom

Survival Surgery

1. * Surgery type:

2.	* Describ	e the surgi	cal procedure	:							
3.		e how the a c surgery:	animal, surge	on and instruments w	ill be prepared						
4. Select the anesthesia, analgesia, antibiotics and/or peri-operative medication to be used:											
	Name	Туре	Version	Scope							
	There are n	o items to disp	olay								
Alternatively, if you cannot find the procedures in the list above, enter the information here: Describe each substance and the step-by-step procedure to be used: (include route, dose, volume, concentration, and whether substance is pharmaceutical grade)											

- 5. Describe the anesthetic monitoring:
- 6. Describe immediate post-operative care and monitoring until fully recovered:
- 7. Describe long-term post-operative care and monitoring:

View: SF: Procedure Documents

Procedure Documents

1. Supporting documents:

Document Name

Date Modified

There are no items to display



View: SF: Procedure Identification_custom

Procedure Identification

- : Substance Administration Procedure
 - 1. *Name of the procedure or surgery:

Substance Administration Procedure

- 2. *Select procedure type: Substance Administration
- 3. *Species:
- 4. *Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):

View: SF: Administration of Substances

Administration of Substances

1. *Substances:

Substance

Substance Scope

Route

Other Route Dose

Dosage Concentration Volume Complication Frequency

Remediation

Substance Order for Procedure

- 2. *Describe step-by-step the procedure for administering the substance:
- 3. Describe any anticipated adverse reactions to administering the substances:
- 4. * Are all substances being administered in this procedure of pharmaceutical grade?

Yes No

- a. * For each non-pharmaceutical grade substance, provide justification for not using the pharmaceutical grade:
- **b.** * For each non-pharmaceutical grade substance, describe the procedures to be used to ensure the sterility, purity, stability and physiologic pH of the compound:
- C. For each non-pharmaceutical grade substance, describe the storage method, if any:
- 5. Select the anesthesia and analgesia procedures to be used:

There are no items to display

Alternatively, if you cannot find the procedures in the list above, enter the information here:

Describe each substance and the step-by-step procedure to be used: (include route, dose, volume, concentration, and whether substance is pharmaceutical grade)

- 6. Describe the monitoring of the animal during the procedure:
- 7. Describe post-procedural care and monitoring:

View: SF: Procedure Documents

Procedure Documents

1. Supporting documents:

Document Name

Date Modified



View: SF: Procedure Identification_custom

Procedure Identification

- : Physical Restraint Procedure
 - 1. * Name of the procedure or surgery:

Physical Restraint Procedure

- 2. * Select procedure type: Physical Restraint
- 3. * Species:
- 4. * Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):

View: SF: Prolonged Physical Restraint_custom

Prolonged Physical Restraint

2. *Justify the use of the restraint:

pharmaceutical grade)

6. Describe the anesthetic monitoring:

1. *Describe the restraint devices and how they will be used:

3. Describe the acclimation procedure: (include plan for identifying acclimation and handling failure to acclimate)							
4. Describe the monitoring frequency during restraint, including weekends and holidays:							
5. Select the anesthesia and analgesia procedures to be used:							
Name Type Version Scope							
There are no items to display							
Alternatively, if you cannot find the procedures in the list above, enter the information here: Describe each substance and the step-by-step procedure to be used:							

(include route, dose, volume, concentration, and whether substance is

View: SF: Procedure Documents

Procedure Documents

1. Supporting documents:

Document Name

Date Modified

There are no items to display



View: SF: Procedure Identification_custom

Procedure Identification

- : Tissue/Blood Collection Procedure
 - 1. * Name of the procedure or surgery:

Tissue/Blood Collection Procedure

- 2. * Select procedure type: Tissue/Blood Collection
- 3. * Species:
- 4. *Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):

2. Describe timing and frequency of collection and amount to be

3. Select the anesthesia and analgesia procedures to be used:

View: SF: Tissue/Blood Collection_custom

Tissue/Blood Collection

collected:

1. *Identify tissues to be collected:

annot find the procedures in the list above, enter the
nnot find the procedures in the list above, enter the
tance and the step-by-step procedure to be used: volume, concentration, and whether substance is
<u>tic</u> monitoring:
<u>no</u> monitoring.
lural care and monitoring:
al complications from collection:
tion procedure:
lural care and monitoring:

View: SF: Procedure Documents

Procedure Documents

1. Supporting documents:

Document Name

Date Modified

There are no items to display



View: SF: Procedure Identification_custom

Procedure Identification

- : Monitoring Disease Models Procedure
 - 1. *Name of the procedure or surgery:

Monitoring Disease Models Procedure

- 2. *Select procedure type: Monitoring Disease Models
- 3. *Species:
- 4. *Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):

View: SF: Monitoring Disease Models Procedures_custom

Monitoring Disease Models Procedures

- 1. Describe the anticipated progression of the disease, including onset of clinical signs and expected mortality rate:
- 2. Describe frequency of monitoring upon onset of clinical signs:
- 3. Describe what will be monitored:
- 4. Described the criteria to be used to identify humane endpoints:

View: SF: Procedure Documents

Procedure Documents

1. Supporting documents:

Document Name

Date Modified

There are no items to display



View: SF: Procedure Identification_custom

Procedure Identification

- : Food or Fluid Restriction Procedure
 - 1. *Name of the procedure or surgery:

Food or Fluid Restriction Procedure

- 2. *Select procedure type: Food or Fluid Restriction
- 3. *Species:
- 4. *Will administering this procedure cause any more than momentary pain and distress?

Yes No

If yes,

i. Identify expected or potential clinical signs from administering this procedure (include anticipated animal loss, if applicable):

View: SF: Food or Fluid Restriction

Food or Fluid Restriction

1. * Restrictions:

- 2. *How many hours will the food/fluid be restricted:
- 3. * Describe the procedure for providing food/fluid including schedules and amounts:
- 4. * Describe criteria for monitoring the health of animals while on food/fluid restriction:
- 5. * Provide justification for restricting food/fluid to the extent defined:
- 6. Describe what will happen if animals fail to meet selected health criteria:

View: SF: Procedure Documents

Procedure Documents

1. Supporting documents:

Document Name

Date Modified

There are no items to display

Substances Appendix:



View: SF: Substance Information

Substance Information

- 1. *Name:
- 2. * Substance types: (select all that apply)
- 3. Is this a hazardous agent:

*

4. Supporting documents:

Document Name

Date Modified

There are no items to display

View: Create and Edit_custom

Experiments Appendix:

*	•			
	1.	*Experiment name:		
	2.	*Species:		
	3.	Justify the purpose of this	experiment:	
	4.	experimental animals, live-	-born offspring, an	s must be counted, including ad animals that are produced in search. Click here for guidance.
	5.	-	tical analysis, pilot	ased on study type (studies study, tissue harvest required
	6.	Select common procedure	s: (applied to all an	imals in the experiment)
		Name	Туре	Version Scope

1.	animals in the experiment)						
	a. Se	ect the va	riable proc	edures:			
	Na	me	Туре	Version	Scope		
	Th	ere are no	items to d	isplay			
	b. De	scribe the	variables o	of the experim	nent:		
8.	Describe	e any vari	ations to t	he selected :	standard procedure	s:	
9.	Procedu	ıre Timing	/Chronolo	ogy:			
10.	⋆ Total n be produ		animals u	sed in this e	xperiment: (including	ງ all the animals to	
11.		of anima l pain catego		category: (in	clude each animal on	ly once in the	
12.	a justifid tranquil	cation for izer drugs	why the u	se of approp versely affec	eviated pain/distress riate anesthetic, and of the procedure res	algesic, or	
13		_	n dry exce p Descr	otions: ription and Jus	stification		
14	4. Supp	orting do	cuments:				

4. Importation protocol

			Docket No. A-
	TO THE U	IMMS ANI	/ERTEBRATE ANIMALS MAL FACILITY
	UMMS Institut	ional Animal Ca	re and Use Committee
Principal Investigator (PI)	Name and Highest Academic Degree(s)		
	Faculty Title		
	Department \ Division or Company Name		
	Mailing Address or UMMS Building		
	E-mail Address		
	Contact Phone Numbers	Office:	Pager #: Home:
Faculty Sponsor (if required) or co- investigator	Name and Degree		
	Faculty Title		
	Department/Division		
Protocol Title		<u> </u>	-
			Name of Department Chair (Please Print or Type)
Signature of Depa	rtment Chair	- Date	
For IACUC USE ONL			
Approved:	Yes No		
Approved with cond			
Date	Chair/Vice C	hair, IACUC	

 A. A. C. Marcheller 	ion I. OBJECTIVES		
a. Brie	fly explain why animals are kept under	an importation protocol.	
Secti	on II. SPECIES, SOURCE AND	ANIMAL NUMBERS	
a. Desc	ribe the species, age and weight, and tation protocol are considered to be	the number of animals being h	eld. Note that all animals held under the not used in experiments, teaching or
	s/strain	Age	Number of animals
b. Indic	eate the source of animals below.		
Specie	s/strain	Animal source (na	ame of the commercial vendor/institution)
associ	cipated health problems in the animals ated with the animals under this protoc	ol, please describe them in de	tail.
d. If yo	ur animals have special needs, use this	s space to list needs for specia	l handling or housing.
e. Will	your animals require special caging?		
1 4 1 12 1	on III. APPLICANT'S CERTIFI	CATION	
gover		research and instruction. A	Federal Government's Animal Welfare Act ccordingly, the Applicant, holding the Pl
BY SI	GNING BELOW, I CERTIFY THE	FOLLOWING:	
1.	by the provisions of the PHS/NIH	Guide for the Care and Use	se of animals in instruction and research, of Laboratory Animals, and by all other of animals in instruction and research.
2.	I understand that the animals und Medicine, and I or my parent Depa		I be cared for by the Department of Animal all the expenses.
3.	If animals in this project show evi be administered at the discretion		ergency care, including euthanasia, may erinary staff.
4.	This application meets all animal asked to support the research.	use and care requirements	of the funding agencies that have been
Pl's Si	gnature:		Date:

5. Holding Protocol

IACUC Animal Transfer Addendum

Holding Protocol Transfer Id #:

The animals held under the IACUC Holding Protocol will be identified by a unique Holding Protocol Transfer Id # that reflects the IACUC Blanket Protocol number, 1910, followed by the original Animal Study Protocol number. For example, the Id # 1910, 1000-12 designates animals transferred from the protocol A-1000-12.

Notes to the Principal Investigator of the expired Animal Study Protocol

IACUC approved animal protocols are only valid for a maximum period of 3 years, and they cannot be extended. All Principal Investigators (PIs) are required to submit renewal applications for IACUC review and approval within 3 years. In the event that IACUC approval is not obtained before the protocol expiration date, the Department of Animal Medicine will transfer the remaining animals from the expired protocol to this holding protocol.

The animals in the holding protocol will be cared for by the Department of Animal Medicine. The PIs will be responsible for the applicable animal care charges. Animal care per diem charges during this period are not allowable costs for Federal Govt. grants. While animals are kept under this holding protocol, no animal activity (experimentation, breeding and euthanasia) is permitted. The PIs are required to transfer the animals to their IACUC approved protocols within 3 months or the animals may be euthanized by the Department of Animal Medicine at the discretion of the IACUC in accordance with the current UMMS IACUC Holding Protocol Policy.

Name of the Principal Investiga	tor (PI) of the			
expired IACUC Protocol		1_		
Expired Animal Protocol Number	er			
Protocol Expiration Date				
Project Title				
Details of animals transferred	i		·	
Species/strain	Age		Number of animals transferred	
Anticipated health problems,	PI is resp	onsible for com	municating this information in	
special animal care or housing	_	writing to the Department of Animal Medicine (refer to the		
requests or special needs	above Tra	above Transfer Id# in your communication)		
			·	
Effective Date:	S	Signature of the IACUC Chair:		
If animals are transferred to	PI name:			
an IACUC approved protocol	Protocol numb	otocol number:		
	Approval Date	<u>:</u>		
If animals are euthanized by Number of anim		mals euthanize	d:	
the Department of Animal	Date of euthan	e of euthanasia:		
Medicine				

-	Appendix 9: IACUC/OB Protoco	ol Form
6. Off-site Protocol		

UMMS Inst	ATION FOR OFF itutional Animal Care a otocol is required for anima	and Use Committe		cket No. A-
Principal	Name and Highest Acad	100 to 10	:	the artists that the second of
Investigator			•	
	Department \ Division or	Company Name		
	Mailing Address or UMM			
	E-mail Address			
	Phone Numbers	-		
Primary	Name			
Contact	E-mail Address			
Project				
Title				
	NT'S CERTIFICATION	18 March 19 18 18 18 18 18 18 18 18 18 18 18 18 18		
BY CHECK	(ING AND SIGNING E	BELOW, I CERTIF	Y THE FOLLOWING:	
must be a All off-site The studi committee To the be agencies I agree to	conducted on living animal e animal studies will take p ies has been reviewed and es in compliance with fede est of my knowledge, my co that have been asked to so maintain IACUC approva	s. lace at NIH Assured I lapproved, and will be ral laws. cllaborators at off-site support the research. I at the outside institut CUC of any changes i	nstitutions. e overseen by another IACU facilities meet all animal use ion as long as the project re n the status of my off-site st	re not available, and that the research IC or similar institutional oversight e and care requirements of the funding emains active. udies and IACUC approval associated
Pl's Signature	-		Date:	
GRANTS	ASSOCIATED WITH	The second of th	E ANIMAL STUDY	[1] 大学 [2] 第二次 <u>- 建筑</u> 庭
	Sponsor Funding period			Grant ID#

OBJECTIVES OF	PROPOSED RESEARCH		
Lay Summary: In a few l	orief sentences, concisely summarize the objectives of your a	nimal studies, using, <u>non-tec</u>	hnical,
language (i.e., that could	be understood by someone at a high school level),		
Scientific Summan: Bris	efly summarize the aims and scientific approaches to be used.		
Ocientino Guininary. Dire	sny summanze the aims and scientific approaches to be used.		
ANIMALIAMORICE	OONE OUTSIDE UMMS	gradina di Arabana di A	
	Provide a brief description of the animal work done	I IACUC Protocol number	Animal
Institution/company Pl/contact Contact information	Provide a prier description of the animal work done	PHS Assurance number, if applicable	Species
Contact information		паррисавие	
	,		
For office use only:			
•	-A-1II		
Additional documents of	otained:		

MOU: Memorandum of understanding LETTER: Letter from the collaborator/company APPROVAL: Copy of the IACUC approval PROTOCOL: Copy of the IACUC protocol

Name of the institution:

Name of the institution:

Name of the institution:

ENGLISH: English translation of the animal study protocol

☐ MOU ☐ LETTER ☐ APPROVAL ☐ PROTOCOL ☐ ENGLISH

 \square MOU \square LETTER \square APPROVAL \square PROTOCOL \square ENGLISH

☐ MOU ☐ LETTER ☐ APPROVAL ☐ PROTOCOL ☐ ENGLISH

7. Unanticipated Adverse Event(s) Form

Unanticipated Adverse Event Report

Institutional Animal Care and Use CommitteeUniversity of Massachusetts Medical School

IACUC Protocol Number Species Principal Investigator Today's Date
Date when the unanticipated adverse event was first identified:
2. Date when the unanticipated adverse event was reported to the Principal Investigator (or that person's designee):
3. Describe the unanticipated adverse event.
4. What were the circumstances that led to the unanticipated adverse event? Please check one of the following and explain:
Drug/Device RelatedProcedure RelatedOther Reasons
5. If not already described above, how many animals were affected? In which experimental group were these animals? What percentage of the animals in the experimental group experienced the unanticipated adverse event?
6. Describe the corrective actions you took or will take to remedy the situation and ensure that this event winot repeat itself?
Principal Investigator's Signature: